Advertisement

Leishmania pp 265-277 | Cite as

In Vitro Infections of Macrophage-Like Cell Lines with Leishmania infantum for Drug Screening

  • Nuno Santarém
  • Joana Tavares
  • Anabela Cordeiro-da-SilvaEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1971)

Abstract

The study of in vitro infections is essential to evaluate distinct aspects of Leishmania biology and also invaluable for more meaningful in vitro screening of promising chemical entities. Macrophage-like cells lines from different origins are amenable to Leishmania infection. Cell lines due to their stability and standardization potential are highly valued for their capacity to support reproducible infections and consistent data. In fact, these cells have been a mainstay of leishmaniasis research for more than 40 years. In this context, the human monocytic THP-1 cell line is commonly used as it can be differentiated with phorbol-12myristate-13-acetate (PMA) into macrophages that are susceptible to Leishmania infection. In this section, we will describe generalities concerning the use of cell lines for in vitro Leishmania infection using THP-1 derived macrophages and Leishmania infantum axenic amastigotes expressing luciferase associated to preclinical drug screening as example.

Key words

Leishmania Macrophage-like cell lines Drug screening Axenic amastigotes 

Notes

Acknowledgments

This work was supported by funds from the Fundação para a Ciência e Tecnologia (FCT)/Ministério da Educação e Ciência (MEC) cofunded by the European Regional Development Fund (FEDER) under the Partnership agreement PT2020, through the Research Unit No.4293. This work also received funds from project POCI-01-0145-FEDER-031013 financed by Portugal 2020, under the Programa Operacional Competitividade e Internacionalização (COMPETE 2020) and Norte-01-0145-FEDER-000012—Structured program on bioengineered therapies for infectious diseases and tissue regeneration, supported by Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the FEDER. J.T. is an Investigator FCT funded by National funds through FCT and cofunded through European Social Fund within the Human Potential Operating Programme.

References

  1. 1.
    WHO (2017) Leishmaniasis. http://www.who.int/leishmaniasis/en/. Accessed 30 Nov 2017.
  2. 2.
    Edmondson R, Broglie JJ, Adcock AF, Yang L (2014) Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol 12(4):207–218.  https://doi.org/10.1089/adt.2014.573CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Zulfiqar B, Shelper TB, Avery VM (2017) Leishmaniasis drug discovery: recent progress and challenges in assay development. Drug Discov Today 22(10):1516–1531.  https://doi.org/10.1016/j.drudis.2017.06.004CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    De Muylder G, Ang KK, Chen S, Arkin MR, Engel JC, McKerrow JH (2011) A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit. PLoS Negl Trop Dis 5(7):e1253.  https://doi.org/10.1371/journal.pntd.0001253CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Nuhs A, De Rycker M, Manthri S, Comer E, Scherer CA, Schreiber SL, Ioset JR, Gray DW (2015) Development and validation of a novel Leishmania donovani screening cascade for high-throughput screening using a novel axenic assay with high predictivity of leishmanicidal intracellular activity. PLoS Negl Trop Dis 9(9):e0004094.  https://doi.org/10.1371/journal.pntd.0004094CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Shafi S, Afrin F, Islamuddin M, Chouhan G, Ali I, Naaz F, Sharma K, Zaman MS (2016) Beta-nitrostyrenes as potential anti-leishmanial agents. Front Microbiol 7:1379.  https://doi.org/10.3389/fmicb.2016.01379CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Santarem N, Cunha J, Silvestre R, Silva C, Moreira D, Ouellette M, Cordeiro-da-Silva A (2014) The impact of distinct culture media in Leishmania infantum biology and infectivity. Parasitology 141(2):192–205.  https://doi.org/10.1017/S0031182013001388CrossRefPubMedGoogle Scholar
  8. 8.
    Maia C, Rolao N, Nunes M, Goncalves L, Campino L (2007) Infectivity of five different types of macrophages by Leishmania infantum. Acta Trop 103(2):150–155.  https://doi.org/10.1016/j.actatropica.2007.06.001CrossRefPubMedGoogle Scholar
  9. 9.
    Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K (1980) Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 26(2):171–176CrossRefGoogle Scholar
  10. 10.
    Ogunkolade BW, Colomb-Valet I, Monjour L, Rhodes-Feuillette A, Abita JP, Frommel D (1990) Interactions between the human monocytic leukaemia THP-1 cell line and Old and New World species of Leishmania. Acta Trop 47(3):171–176CrossRefGoogle Scholar
  11. 11.
    Sundstrom C, Nilsson K (1976) Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 17(5):565–577CrossRefGoogle Scholar
  12. 12.
    Gupta S, Yardley V, Vishwakarma P, Shivahare R, Sharma B, Launay D, Martin D, Puri SK (2015) Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis. J Antimicrob Chemother 70(2):518–527.  https://doi.org/10.1093/jac/dku422CrossRefPubMedGoogle Scholar
  13. 13.
    Ralph P, Moore MA, Nilsson K (1976) Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines. J Exp Med 143(6):1528–1533CrossRefGoogle Scholar
  14. 14.
    Pratt DM, David JR (1982) Monoclonal antibodies recognizing determinants specific for the promastigote state of Leishmania mexicana. Mol Biochem Parasitol 6(5):317–327CrossRefGoogle Scholar
  15. 15.
    Kolodziej H, Kiderlen AF (2005) Antileishmanial activity and immune modulatory effects of tannins and related compounds on Leishmania parasitised RAW 264.7 cells. Phytochemistry 66(17):2056–2071.  https://doi.org/10.1016/j.phytochem.2005.01.011CrossRefPubMedGoogle Scholar
  16. 16.
    Raschke WC, Baird S, Ralph P, Nakoinz I (1978) Functional macrophage cell lines transformed by Abelson leukemia virus. Cell 15(1):261–267CrossRefGoogle Scholar
  17. 17.
    Nandan D, Lo R, Reiner NE (1999) Activation of phosphotyrosine phosphatase activity attenuates mitogen-activated protein kinase signaling and inhibits c-FOS and nitric oxide synthase expression in macrophages infected with Leishmania donovani. Infect Immun 67(8):4055–4063PubMedPubMedCentralGoogle Scholar
  18. 18.
    Wellman ML, Krakowka S, Jacobs RM, Kociba GJ (1988) A macrophage-monocyte cell line from a dog with malignant histiocytosis. In Vitro Cell Dev Biol 24(3):223–229CrossRefGoogle Scholar
  19. 19.
    Looker DL, Martinez S, Horton JM, Marr JJ (1986) Growth of Leishmania donovani amastigotes in the continuous human macrophage cell line U937: studies of drug efficacy and metabolism. J Infect Dis 154(2):323–327CrossRefGoogle Scholar
  20. 20.
    Lund ME, To J, O'Brien BA, Donnelly S (2016) The choice of phorbol 12-myristate 13-acetate differentiation protocol influences the response of THP-1 macrophages to a pro-inflammatory stimulus. J Immunol Methods 430:64–70.  https://doi.org/10.1016/j.jim.2016.01.012CrossRefPubMedGoogle Scholar
  21. 21.
    Borsari C, Santarem N, Torrado J, Olias AI, Corral MJ, Baptista C, Gul S, Wolf M, Kuzikov M, Ellinger B, Witt G, Gribbon P, Reinshagen J, Linciano P, Tait A, Costantino L, Freitas-Junior LH, Moraes CB, Bruno Dos Santos P, Alcantara LM, Franco CH, Bertolacini CD, Fontana V, Tejera Nevado P, Clos J, Alunda JM, Cordeiro-da-Silva A, Ferrari S, Costi MP (2017) Methoxylated 2′-hydroxychalcones as antiparasitic hit compounds. Eur J Med Chem 126:1129–1135.  https://doi.org/10.1016/j.ejmech.2016.12.017CrossRefPubMedGoogle Scholar
  22. 22.
    ATCC THP1(ATCC TIB-202). https://www.lgcstandards-atcc.org/products/all/TIB-202.aspx. Accessed 4 Jan 2018.
  23. 23.
    Seifert K, Escobar P, Croft SL (2010) In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent. J Antimicrob Chemother 65(3):508–511.  https://doi.org/10.1093/jac/dkp500CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Sereno D, Lemesre JL (1997) Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob Agents Chemother 41(5):972–976CrossRefGoogle Scholar
  25. 25.
    Aldo PB, Craveiro V, Guller S, Mor G (2013) Effect of culture conditions on the phenotype of THP-1 monocyte cell line. Am J Reprod Immunol 70(1):80–86.  https://doi.org/10.1111/aji.12129CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Wenger SL, Senft JR, Sargent LM, Bamezai R, Bairwa N, Grant SG (2004) Comparison of established cell lines at different passages by karyotype and comparative genomic hybridization. Biosci Rep 24(6):631–639.  https://doi.org/10.1007/s10540-005-2797-5CrossRefPubMedGoogle Scholar
  27. 27.
    Briske-Anderson MJ, Finley JW, Newman SM (1997) The influence of culture time and passage number on the morphological and physiological development of Caco-2 cells. Proc Soc Exp Biol Med 214(3):248–257CrossRefGoogle Scholar
  28. 28.
    Moreira D, Santarem N, Loureiro I, Tavares J, Silva AM, Amorim AM, Ouaissi A, Cordeiro-da-Silva A, Silvestre R (2012) Impact of continuous axenic cultivation in Leishmania infantum virulence. PLoS Negl Trop Dis 6(1):e1469.  https://doi.org/10.1371/journal.pntd.0001469CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Ali KS, Rees RC, Terrell-Nield C, Ali SA (2013) Virulence loss and amastigote transformation failure determine host cell responses to Leishmania mexicana. Parasite Immunol 35(12):441–456.  https://doi.org/10.1111/pim.12056CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Nuno Santarém
    • 1
    • 2
  • Joana Tavares
    • 1
    • 2
  • Anabela Cordeiro-da-Silva
    • 1
    • 2
    • 3
    Email author
  1. 1.i3S-Instituto de Investigação e Inovação em SaúdeUniversidade do PortoPortoPortugal
  2. 2.IBMC–Instituto de Biologia Molecular e Celular, Parasite Disease GroupUniversidade do PortoPortoPortugal
  3. 3.Departamento de Ciências Biológicas, Faculdade de FarmáciaUniversidade do PortoPortoPortugal

Personalised recommendations